Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA–a retrospective study of claims data from 2009 to 2020
- 2 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 40 (10), 4061-4070
- https://doi.org/10.1007/s10067-021-05713-8
Abstract
Objectives To compare healthcare resource utilization and costs among patients with psoriasis, psoriatic arthritis (PsA), and a control group of patients without psoriasis and PsA in the USA. Methods The IBM® MarketScan® Commercial Database was used to identify three adult patient groups from 1/1/2009 through 4/30/2020: (1) Psoriasis: ≥ 2 diagnoses ≥ 30 days apart for psoriasis (no PsA diagnoses); (2) PsA: ≥ 2 diagnoses for PsA; (3) Control: no psoriasis or PsA diagnoses in their entire claims records. Patients with comorbid rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, or ulcerative colitis were excluded from the analyses. Controls were matched 1:1 to psoriasis and PsA patients based on age, gender, index year, and number of non-rheumatological comorbidities. Healthcare resource utilization and costs (in 2019 USD) were evaluated descriptively and through mixed models for five years of follow-up. Results A total of 142,531 psoriasis and 21,428 PsA patients were matched to the control group (N = 163,959). Annual all-cause healthcare costs per patient were $7,470, $11,062, and $29,742 for the control, psoriasis, and PsA groups, respectively. All-cause healthcare costs increased over time and were significantly greater among PsA vs. psoriasis (p < 0.0001) and the control groups (p < 0.0001). Across all categories of healthcare resources, utilization was greatest among patients with PsA and lowest in the control group. Conclusion Annual healthcare costs and resource utilization were significantly higher with PsA compared with psoriasis and the control group, confirming the substantial economic burden of PsA. The cost disparity between these patient groups highlights a continued unmet medical need. Key Points • Patients with PsA incurred significantly greater healthcare resource utilization and costs than patients with psoriasis and patients without psoriasis and PsA. • Significantly greater costs and healthcare resource utilization were also observed among patients with psoriasis compared with patients without psoriasis and PsA.Funding Information
- Janssen Pharmaceutica
This publication has 24 references indexed in Scilit:
- Critical role of environmental factors in the pathogenesis of psoriasisThe Journal of Dermatology, 2017
- Current Concepts in Psoriatic Arthritis: Pathogenesis and ManagementActa Dermato-Venereologica, 2014
- Psoriasis prevalence among adults in the United StatesJournal of the American Academy of Dermatology, 2014
- Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinicsJournal of the American Academy of Dermatology, 2013
- Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta‐Analysis of Observational StudiesJournal of the American Heart Association, 2013
- Pathogenesis and therapy of psoriasisNature, 2007
- European patient perspectives on the impact of psoriasis: the EUROPSO patient membership surveyBritish Journal of Dermatology, 2006
- Aetiology and pathogenesis of psoriasisBritish Journal of Dermatology, 1996
- Disease concomitance in psoriasisJournal of the American Academy of Dermatology, 1995
- A population genetic study of psoriasisBritish Journal of Dermatology, 1994